Definiens Closes €10 Million Round to Grow its Clinical Digital Pathology Business
News Oct 02, 2012
Existing investors, including TVM, Cipio and Definiens’ management also participated in the financing round.
Definiens will primarily use the funding for commercial expansion of its current business and to develop and commercialize innovative products for Clinical Digital Pathology. The company’s solutions are currently being used for research and development by all major pharmaceutical companies as well as an increasing number of diagnostic companies in tissue based diagnostic biomarker development.
Dr Janke Dittmer, partner at Gilde Healthcare Partners, has joined the Company’s Supervisory Board.
“This new round of funding allows Definiens’ to grow its Clinical Digital Pathology business,” said Thomas Heydler, CEO of Definiens. “Gilde Healthcare Partners joins our team of committed investors. With their financial support and partnership, we will build on the success of our existing business and increase our presence in the clinical routine use of Digital Pathology.”
“Digital Pathology combined with the right image analysis tools has the potential to transform cancer diagnosis. As the market leader in image analysis for Digital Pathology Definiens is well positioned to unlock the full potential of tissue based diagnostics and drive the clinical adoption of quantitative Digital Pathology.” said Janke Dittmer. “We led this investment round because we believe that Definiens has a set of market leading products, a strong patent portfolio and unique capabilities to turn new concepts into clinically relevant products which will benefit people suffering from cancer around the world.”
Definiens’ proprietary Cognition Network Technology® enables best in class analysis of Digital Pathology images, but can also be used on other types of images. It is the brainchild of Definiens' founder, CTO and Nobel Laureate Prof Dr Gerd Binnig. Its context based segmentation approach leads to unsurpassed accuracy in detecting structures of interest and is robust with regard to variations in the tissue and the scanner used.
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE